Beryl Drugs Ltd

Beryl Drugs Annual Report

Beryl Drugs Ltd has submitted its 33rd Annual Report for the financial year 2025-26, scheduled for its upcoming Annual General Meeting.

Beryl Drugs Annual General Meeting

Beryl Drugs Ltd has announced the closure of its register of members from September 23 to September 29, 2026, for its 33rd Annual General Meeting.

Beryl Drugs Board Meeting Outcome

Beryl Drugs Limited approved items for its 33rd Annual General Meeting and a proposal to increase material related party transaction limits.

Beryl Drugs Board Meeting Date

Beryl Drugs Ltd has scheduled a Board Meeting for September 2, 2026, to approve the Board report and matters related to its 33rd Annual General Meeting.

Beryl Drugs Promoter Buying

Sudhir Sethi, a promoter of Beryl Drugs Limited, acquired 3,000 equity shares via market transactions. This acquisition increases the promoter's total stake from 10.08% to 10.14%.

Beryl Drugs Q1 FY27 Results: Net Profit ₹0.2 Cr, Down 66.7% QoQ

Beryl Drugs Ltd reported revenue from operations of ₹7.3 Cr (+52.1% YoY) and net profit of ₹0.2 Cr for Q1 FY27.

Key figure

Net profit ₹0.2 Cr

Beryl Drugs Board Meeting Outcome

Beryl Drugs Ltd's board meeting on August 11, 2026, approved the unaudited financial results for the quarter ended June 30, 2026.

Beryl Drugs Board Meeting Date

Beryl Drugs Ltd's Board of Directors will meet on August 11, 2026, to approve unaudited financial results for the quarter ended June 30, 2026.

Beryl Drugs Adverse Business Impact

Beryl Drugs Ltd reported the temporary unavailability of its corporate website due to technical issues. The company stated there is no impact on business operations.

Beryl Drugs Promoter Buying

Promoter Sudhir Sethi acquired 6,950 shares of Beryl Drugs Ltd via market transactions. This increases the promoter's stake by 0.14% to a total of 10.055%.

Beryl Drugs Capacity Expansion

Beryl Drugs Ltd will shift its registered office within Indore to Neer Nagar effective 1 July 2026. The change is for administrative convenience and leaves the CIN unchanged.

Beryl Drugs Board Meeting Outcome

Beryl Drugs Ltd approved relocation of its registered office within Indore. The move does not affect operations but updates the company's registered address.

Beryl Drugs Board Meeting Date

Beryl Drugs scheduled a board meeting for June 16, 2026. The board will consider shifting the company's registered office within the local limits of Indore.

Beryl Drugs Promoter Buying

Promoter Mr. Sudhir Sethi acquired 1,992 equity shares of Beryl Drugs Limited through open market transactions. The purchase increases his total stake to 9.75%.

Beryl Drugs Q4 FY26 Results: Net Profit ₹0.6 Cr, Up 200.0% YoY

Beryl Drugs Ltd reported revenue from operations of ₹5.5 Cr (+5.8% YoY) and net profit of ₹0.6 Cr (+200.0% YoY) for Q4 FY26.

Key figure

Net profit ₹0.6 Cr · +200.0% YoY

Beryl Drugs Financial Results

Beryl Drugs reported annual revenue of ₹19.31 Crore for FY2026. The results include an unmodified audit opinion despite temporary manufacturing suspensions in the BFS section.

Value

₹19.31 Cr

Beryl Drugs Board Meeting Outcome

Beryl Drugs Ltd approved its audited financial statements and related party transactions during its board meeting. Results for the fiscal year ended March 2026 were confirmed.

Beryl Drugs Board Meeting Date

Beryl Drugs Ltd scheduled a board meeting on May 28, 2026, to approve audited financial results. The meeting will also consider related party transactions.

Beryl Drugs Annual General Meeting

Beryl Drugs Limited concluded its Extra-Ordinary General Meeting on May 11, 2026. Shareholders approved director appointments and material related party transactions through remote e-voting and polling.

Beryl Drugs Annual General Meeting

Beryl Drugs Limited shareholders approved all resolutions at the May 11 EGM with 100% favor. Appointments and related party transactions were passed unanimously by the company.

Beryl Drugs Annual General Meeting

Beryl Drugs Limited shareholders approved new director appointments and material related party transactions during the EGM. The meeting concluded successfully with all requisite majorities.

Beryl Drugs Other Announcement

Beryl Drugs Ltd submitted a certificate claiming exemption from Corporate Governance provisions under Regulation 15(2) of SEBI LODR for the year ended March 31, 2026. The company qualifies for the exemption as its paid-up capital (₹5.07 Crore) and net worth (₹9.50 Crore) remain below the prescribed regulatory thresholds.

Beryl Drugs Debt & Borrowing: ₹2.39 Cr

Beryl Drugs Ltd (BSE: 524606) has submitted its initial disclosure confirming it is not identified as a Large Corporate as of March 31, 2026. The company reported outstanding borrowings of ₹2.39 Crore, falling below the SEBI threshold for large corporate classification.

Value

₹2.39 Cr

Beryl Drugs Other Announcement

Beryl Drugs Ltd has submitted its quarterly compliance reports for the period ended March 31, 2026. The filing includes certificates regarding dematerialisation of securities and maintenance of share transfer facilities. These are routine regulatory submissions ensuring administrative and operational transparency for shareholders.

Beryl Drugs Other Announcement

Beryl Drugs Ltd submitted compliance certificates for the quarter and year ended March 31, 2026. The filings confirm maintenance of share transfer facilities by Adroit Corporate Services and compliance with SEBI depository and non-applicability regulations.